Abstract
Glioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until the introduction of temozolomide. The success of this combination has stimulated the search for other candidate drugs for concomitant use with RT in GBM. This review seeks to collate the current evidence for these agents and synthesize possible future directions for the field.
Original language | English |
---|---|
Article number | CNS86 |
Number of pages | 13 |
Journal | CNS Oncology |
Volume | 11 |
Issue number | 2 |
Early online date | 23 May 2022 |
DOIs | |
Publication status | Published - Jun 2022 |
Keywords
- Review
- chemotherapy
- glioblastoma
- radiosensitizers
- radiotherapy
- trial design
Fingerprint
Dive into the research topics of 'Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review'. Together they form a unique fingerprint.Student theses
-
Biophysical correlates of base-mediated radiation cardiotoxicity in non-small cell lung cancer
Walls, G. M. (Author), Butterworth, K. (Supervisor), Jain, S. (Supervisor) & Cole, A. (Supervisor), Jul 2023Student thesis: Doctoral Thesis › Doctor of Philosophy
File